Tryptophan

Tryptophan

SCHEMBL1996751

N[C@@H](Cc1c[nH]c2ccccc12)C(=O)O.N[C@@H](Cc1c[nH]cn1)C(=O)O.N[C@@H](Cc1ccc(O)cc1)C(=O)O

nearest known ligand 0.63

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 3/20 0.63
KDM4E B2RXH2 3/20 0.63
MAPT P10636 3/20 0.63
LMNA P02545 2/20 0.63
TSHR P16473 2/20 0.63
BLM P54132 2/20 0.63
PMP22 Q01453 2/20 0.63
MEN1 O00255 2/20 0.63
MPO P05164 1/20 0.63
HIF1A Q16665 1/20 0.63
ALDH1A1 P00352 1/20 0.54
CYP3A4 P08684 1/20 0.54
HTR1A P08908 1/20 0.54
ADORA3 P0DMS8 1/20 0.54
ALOX15 P16050 1/20 0.54
NFKB1 P19838 1/20 0.54
HTR2A P28223 1/20 0.54
HTR2C P28335 1/20 0.54
SLC6A4 P31645 1/20 0.54
HTR7 P34969 1/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Dl-Tryptophan SCHEMBL1996746 1.00 KMT2A (0.63) KMT2AKDM4EMAPTLMNATSHR
Tryptophan SCHEMBL1897501 0.99 KMT2A (0.61) KMT2AKDM4EMAPTLMNATSHR
Dl-Tryptophan SCHEMBL1897497 0.99 KMT2A (0.61) KMT2AKDM4EMAPTLMNATSHR
Dl-Tryptophan SCHEMBL22635843 0.96 KMT2A (0.58) KMT2AKDM4EMAPTLMNATSHR
Tryptophan SCHEMBL8634349 0.94 KMT2A (0.68) KMT2AKDM4EMAPTLMNATSHR
Dl-Tryptophan SCHEMBL8634348 0.94 KMT2A (0.68) KMT2AKDM4EMAPTLMNATSHR
Tryptophan SCHEMBL6390462 0.94 KMT2A (0.55) KMT2AKDM4EMAPTLMNATSHR
Dl-Tryptophan SCHEMBL28980603 0.93 KMT2A (0.54) KMT2AKDM4EMAPTLMNATSHR
Dl-Tryptophan SCHEMBL634683 0.92 KMT2A (0.74) KMT2AKDM4EMAPTLMNATSHR
Tryptophan SCHEMBL78589 0.92 KMT2A (0.74) KMT2AKDM4EMAPTLMNATSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8610058-B2 Silver and silver nanoparticle MALDI matrix utilizing online soft landing ion mobility UNIVERSITY OF NORTH TEXAS (US) 2013-12-17 US claimed
US-20120104243-A1 Silver and Silver Nanoparticle MALDI Matrix Utilizing Online Soft Landing Ion Mobillity UNIVERSITY OF NORTH TEXAS (US) 2012-05-03 US claimed
US-8610058-B2 Silver and silver nanoparticle MALDI matrix utilizing online soft landing ion mobility UNIVERSITY OF NORTH TEXAS (US) 2013-12-17 US disclosed
US-20120104243-A1 Silver and Silver Nanoparticle MALDI Matrix Utilizing Online Soft Landing Ion Mobillity UNIVERSITY OF NORTH TEXAS (US) 2012-05-03 US disclosed
EP-2337577-A1 USE OF PITUITARY ADENYLATE CYCLASE-ACTIVATING POLYPEPTIDE (PACAP) AND PACAP ANALOGS AS ADJUNCTIVE TREATMENTS WITH ANTICANCER AGENTS The Administrators of the Tulane Educational Fund (US) 2011-06-29 EP disclosed
WO-2010036936-A2 USE OF PITUITARY ADENYLATE CYCLASE-ACTIVATING POLYPEPTIDE (PACAP) AND PACAP ANALOGS AS ADJUNCTIVE TREATMENTS WITH ANTICANCER AGENTS THE ADMINISTRATORS OF THE TULANE EDUCATIONAL FUND (US) 2010-04-01 WO disclosed
EP-1320594-A2 EXBB-EXBD-TONB GENE CLUSTER OF PSEUDOMONAS PUTIDA DOT-T1E CONFERRING TOLERANCE TO AROMATIC COMPOUNDS AND RESISTANCE TO ANTIBIOTICS E.I. DU PONT DE NEMOURS AND COMPANY (US) 2003-06-25 EP disclosed
WO-2002029034-A2 EXBB-EXBD-TONB GENE CLUSTER OF PSEUDOMONAS PUTIDA DOT-T1E CONFERRING TOLERANCE TO AROMATIC COMPOUNDS AND RESISTANCE TO ANTIBIOTICS NORTH CAROLINA STATE UNIVERSITY (US) 2002-04-11 WO disclosed